Study of LY01015 vs Opdivo with chemo for advanced esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug, LY01015, against Opdivo when both are given with chemotherapy for advanced or metastatic esophageal squamous cell carcinoma. It aims to see if LY01015 works as well as Opdivo and has similar safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have advanced or metastatic esophageal squamous cell carcinoma that cannot be treated with surgery or radiation
- You have not received prior cancer treatment for advanced disease, but earlier treatments for localized cancer are okay if more than 24 weeks ago
- Your tumor shows PD-L1 expression of at least 1%
- You have good overall health (ECOG score 0 or 1) and adequate organ function
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies investigational cancer medicines, either alone or along with pembrolizumab, for people with advanced esophageal squamous cell cancer whose cancer has grown despite prior immune and platinum-based treatment. It may offer a new option after standard therapy has not worked.
This trial tests new drug combinations for people with advanced squamous cell cancer of the esophagus that hasn't been treated yet. It aims to see if these combinations can shrink tumors and help patients live longer.
This trial is testing different treatment combinations before surgery for people with locally advanced esophageal squamous cell carcinoma. The goal is to find which approach works best based on specific biomarkers like PD-L1 levels.
This trial tests a new drug, IPM514, in people with advanced esophageal squamous cell carcinoma whose cancer has worsened after standard treatments like immunotherapy with PD-1/PD-L1 inhibitors and platinum chemotherapy. It aims to see if IPM514 can help when other options have stopped working.
This trial tests a new combination of drugs (SYS6010, enlonstobart, and chemotherapy) as a first treatment for people with advanced esophageal cancer that has not spread elsewhere. It aims to find a more effective option for patients who have not received prior therapy for their advanced disease.
This trial studies giving immunotherapy (anti–PD-1) together with chemotherapy before surgery for certain locally advanced esophageal squamous cell cancer. The goal is to improve how well the tumor responds before and after the operation.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.